Recombinant protein therapeutics—success rates, market trends and values to 2010 (original) (raw)

Nature Biotechnology volume 22, pages 1513–1519 (2004)Cite this article

Despite entering its maturation phase, the recombinant protein sector will continue to drive the growth of medical biotechnology over the next six years.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1: US approval success rates for rDNA therapeutics in two periods.

The alternative text for this image may have been generated using AI.

Bob Crimi

Figure 2: Phase transition probabilities by therapeutic category for rDNA products entering clinical study during 1990–1997.

The alternative text for this image may have been generated using AI.

Bob Crimi

Figure 3: Market growth generated by three business waves and recorded between 2001 and 2003.

The alternative text for this image may have been generated using AI.

Bob Crimi

Figure 4: Therapeutic market segmentation from 2001 to 2003.

The alternative text for this image may have been generated using AI.

Bob Crimi

Figure 5: Distribution of market subsegments generated by the industry's leading recombinant protein brands within the 57% total market share in 2010.

The alternative text for this image may have been generated using AI.

Bob Crimi

Figure 6: Market growth from 2004 to 2010.

The alternative text for this image may have been generated using AI.

Bob Crimi

References

  1. Reichert, J.M. & Paquette, C. Therapeutic recombinant proteins: trends in US approvals 1982-2002. Curr. Opin. Mol. Ther. 5, 139–147 (2003).
    CAS PubMed Google Scholar
  2. Reichert, J.M. Biopharmaceutical approvals in the US. Reg. Affairs J. Pharma 15, 491–497 (2004).
    Google Scholar
  3. Reichert, J.M. & Pavlou, A. Monoclonal antibodies market. Nat. Rev. Drug Discovery 3, 383–384 (2004).
    Article CAS Google Scholar
  4. Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4: 110–118 (2002).
    CAS PubMed Google Scholar
  5. Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819–822 (2001).
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Datamonitor plc., Charles House 108-110 Finchley Road, London, NW3 5JJ
    Alex K Pavlou
  2. Tufts Center for the Study of Drug Development, 192 South Street, Suite 550, Boston, 02111, Massachusetts, USA
    Janice M Reichert

Authors

  1. Alex K Pavlou
  2. Janice M Reichert

Rights and permissions

About this article

Cite this article

Pavlou, A., Reichert, J. Recombinant protein therapeutics—success rates, market trends and values to 2010.Nat Biotechnol 22, 1513–1519 (2004). https://doi.org/10.1038/nbt1204-1513

Download citation

This article is cited by